Talquetamab
Based on 1 publication(s) in Google Scholar
Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2226212-40-2
- 分子量:144.58 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Talquetamab
More
生物活性
Ig(G4-kappa_G4-lambda2)
Human
GPRC5D & CD3E
Talquetamab (0.00128-4.0 μg/mL, 48 h) effectively induces multiple myeloma cell lysis and leads to a significant increase in the proportion of activated CD4+ and CD8+ T cells, as well as to a dose-dependent increase in the levels of granzyme B and inflammatory cytokines such as IL-6, IL-8 and TNF-α[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NSG mice with H929 cells[2]
-
Dosage:0.1-10 µg (0.005 mg/kg)
-
Administration:Subcutaneous injection; on days 0, 3, 5, 7, and 10
-
Result:Completely blocked tumor formation at 1 μg and 10 μg doses.
-
Animal Model:Female NSG mice with human MM cells[2]
-
Dosage:0.1-50 µg (0.005 mg/kg)
-
Administration:Intravenous injection; on days 15, 18, 22, 24, 29, 32, and 36
-
Result:Significantly inhibited tumor growth by 65% at the dose of 1μg and showed significant anti-tumor activity at 10 and 50 μg with complete tumor regression.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human Ig(G4-kappa_G4-lambda2)
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 2226212-40-2
-
性状 Liquid
-
分子量 144.58 kDa
-
Color Colorless to light yellow
-
SMILES
[Talquetamab]
-
別名
JNJ-64407564
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
MAbs
Optimizing human FcRn mouse models to improve pharmacokinetic evaluation of antibody drug candidates. [Abstract]2026 Dec 31;18(1):2649990. PMID: 41878863
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Christie P M Verkleij, et al. Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma. Blood Adv. 2021 Apr 27;5(8):2196-2215. [Content Brief]
[2]. Kodandaram Pillarisetti, et al. A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020 Apr 9;135(15):1232-1243. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Talquetamab 関連分類
HY-P99394 関連分類
Powered by Bioz